According to a recent press release, risankizumab has been shown to be efficacious and safe in patients with plaque psoriasis who have a suboptimal response to IL-17A inhibitors.
top of page
bottom of page
According to a recent press release, risankizumab has been shown to be efficacious and safe in patients with plaque psoriasis who have a suboptimal response to IL-17A inhibitors.
Comments